Non-High-Density Lipoprotein Cholesterol and Progression of Chronic Kidney Disease: Results from the KNOW-CKD Study

Overview

Journal Nutrients

Date 2022 Nov 11

PMID 36364966

Authors

Sang Heon Suh

Tae Ryom Oh

Hong Sang Choi

Chang Seong Kim

Eun Hui Bae

Seong Kwon Ma

Kook-Hwan Oh

Young Youl Hyun

Suah Sung

Soo Wan Kim

Affiliations

Soon will be listed here.

Abstract

As the relation between serum non-high-density lipoprotein cholesterol (nHDL) level and renal outcomes has never been investigated in patients with non-dialysis chronic kidney disease (CKD) yet, we here aimed to unveil the association of nHDL with CKD progression. A total of 2152 patients with non-dialysis CKD at stages 1 to 5 from the KNOW-CKD study were categorized into the tertile (i.e., 1st (T1), 2nd (T2), and 3rd (T3) tertiles) by nHDL, and were prospectively analyzed. The primary outcome was the composite renal event, defined as a composite of decline of kidney function or onset of end-stage renal disease. Kaplan-Meier survival curves analysis demonstrated that the cumulative incidence of the composite renal event was significantly increased in T1 and T3, compared to T2 ( = 0.028, by Log-rank test). Cox regression analysis revealed that both T1 (adjusted hazard ratio 1.309, 95% confidence interval 1.074-1.595) and T3 (adjusted hazard ratio 1.272, 95% confidence interval 1.040-1.556) are associated with significantly increased risk of a composite renal event, compared to T2. The restricted cubic spline plot demonstrated a non-linear, U-shaped association between nHDL and the risk of a composite renal event. In conclusion, both low and high serum nHDL levels are associated with increased risk of CKD progression.

Citing Articles

Association between the EHBP1 SNPs and dyslipidemia in the end-stage renal disease patients with dialysis in Chinese Han population.

Lai Y, Liang Z, Wu C, Zhang M, Shi Z, Meng X Lipids Health Dis. 2024; 23(1):422.

PMID: 39731114 PMC: 11681726. DOI: 10.1186/s12944-024-02407-3.

Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview.

Suh S, Kim S Diabetes Metab J. 2023; 47(5):612-629.

PMID: 37482655 PMC: 10555535. DOI: 10.4093/dmj.2023.0067.

References

Fox C, Larson M, Leip E, Culleton B, Wilson P, Levy D . Predictors of new-onset kidney disease in a community-based population. JAMA. 2004; 291(7):844-50. DOI: 10.1001/jama.291.7.844. View

Nam K, Chang T, Joo Y, Kim J, Lee S, Lee C . Association Between Serum High-Density Lipoprotein Cholesterol Levels and Progression of Chronic Kidney Disease: Results From the KNOW-CKD. J Am Heart Assoc. 2019; 8(6):e011162. PMC: 6475054. DOI: 10.1161/JAHA.118.011162. View

Levey A, Eckardt K, Tsukamoto Y, Levin A, Coresh J, Rossert J . Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6):2089-100. DOI: 10.1111/j.1523-1755.2005.00365.x. View

Tsuruya K, Yoshida H, Nagata M, Kitazono T, Hirakata H, Iseki K . Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: analysis in a large Japanese population. Atherosclerosis. 2014; 233(1):260-7. DOI: 10.1016/j.atherosclerosis.2013.12.037. View

Tsuruya K, Yoshida H, Nagata M, Kitazono T, Iseki K, Iseki C . Impact of the Triglycerides to High-Density Lipoprotein Cholesterol Ratio on the Incidence and Progression of CKD: A Longitudinal Study in a Large Japanese Population. Am J Kidney Dis. 2015; 66(6):972-83. DOI: 10.1053/j.ajkd.2015.05.011. View

Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P . Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of.... J Am Soc Echocardiogr. 2005; 18(12):1440-63. DOI: 10.1016/j.echo.2005.10.005. View

Moorhead J, Chan M, El-Nahas M, Varghese Z . Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982; 2(8311):1309-11. DOI: 10.1016/s0140-6736(82)91513-6. View

Yamamoto S, Yancey P, Ikizler T, Jerome W, Kaseda R, Cox B . Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol. 2012; 60(23):2372-9. PMC: 9667707. DOI: 10.1016/j.jacc.2012.09.013. View

Kim J, Kang H, Lee H, Lee Y, Shim J . Comparison of lipid-related ratios for prediction of chronic kidney disease stage 3 or more in Korean adults. J Korean Med Sci. 2012; 27(12):1524-9. PMC: 3524432. DOI: 10.3346/jkms.2012.27.12.1524. View

10.

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

11.

Baigent C, Landray M, Reith C, Emberson J, Wheeler D, Tomson C . The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377(9784):2181-92. PMC: 3145073. DOI: 10.1016/S0140-6736(11)60739-3. View

12.

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

13.

Schaeffner E, Kurth T, Curhan G, Glynn R, Rexrode K, Baigent C . Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003; 14(8):2084-2091. DOI: 10.1681/ASN.V1482084. View

14.

Suh S, Oh T, Choi H, Kim C, Bae E, Ma S . Non-High-Density Lipoprotein Cholesterol and Cardiovascular Outcomes in Chronic Kidney Disease: Results from KNOW-CKD Study. Nutrients. 2022; 14(18). PMC: 9505887. DOI: 10.3390/nu14183792. View

15.

Muntner P, Coresh J, Smith J, Eckfeldt J, Klag M . Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000; 58(1):293-301. DOI: 10.1046/j.1523-1755.2000.00165.x. View

16.

Joles J, van Goor H, van der Horst M, van Tol A, ELEMA J, Koomans H . High lipid levels in very low density lipoprotein and intermediate density lipoprotein may cause proteinuria and glomerulosclerosis in aging female analbuminemic rats. Lab Invest. 1995; 73(6):912-21. View

17.

Gluba-Brzozka A, Franczyk B, Rysz J . Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients. Nutrients. 2019; 11(11). PMC: 6893650. DOI: 10.3390/nu11112820. View

18.

Sonmez A, Yilmaz M, Saglam M, Unal H, Gok M, Cetinkaya H . The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. Lipids Health Dis. 2015; 14:29. PMC: 4407467. DOI: 10.1186/s12944-015-0031-4. View

19.

Moradi H, Vaziri N, Kashyap M, Said H, Kalantar-Zadeh K . Role of HDL dysfunction in end-stage renal disease: a double-edged sword. J Ren Nutr. 2013; 23(3):203-6. PMC: 3664234. DOI: 10.1053/j.jrn.2013.01.022. View

20.

Su X, Kong Y, Peng D . Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. Lipids Health Dis. 2019; 18(1):134. PMC: 6554877. DOI: 10.1186/s12944-019-1080-x. View